These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20824461)

  • 1. National plans and strategies on rare diseases in Europe.
    Taruscio D; Vittozzi L; Stefanov R
    Adv Exp Med Biol; 2010; 686():475-91. PubMed ID: 20824461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tackling rare diseases at European level: why do we need a harmonized framework?
    Taruscio D; Trama A; Stefanov R
    Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EUROPLAN: a project to support the development of national plans on rare diseases in Europe.
    Taruscio D; Gentile AE; De Santis M; Ferrelli RM; Posada de la Paz M; Hens M; Huizer J; Fregonese L; Stefanov R; Bottarelli V; Weinman A; Le Cam Y; Gavhed D; Mincarone P; Bushby K; Frazzica RG; Donati C; Vittozzi L; Jessop E
    Public Health Genomics; 2013; 16(6):278-87. PubMed ID: 24503588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the usability of EUCERD core indicators for rare diseases.
    Ferrelli RM; De Santis M; Gentile AE; Taruscio D
    Ann Ist Super Sanita; 2015; 51(4):342-5. PubMed ID: 26783222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policies and actions to tackle rare diseases at European level.
    Montserrat A; Taruscio D
    Ann Ist Super Sanita; 2019; 55(3):296-304. PubMed ID: 31553326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European recommendations for primary prevention of congenital anomalies: a joined effort of EUROCAT and EUROPLAN projects to facilitate inclusion of this topic in the National Rare Disease Plans.
    Taruscio D; Arriola L; Baldi F; Barisic I; Bermejo-Sánchez E; Bianchi F; Calzolari E; Carbone P; Curran R; Garne E; Gatt M; Latos-Bieleńska A; Khoshnood B; Irgens L; Mantovani A; Martínez-Frías ML; Neville A; Rißmann A; Ruggeri S; Wellesley D; Dolk H
    Public Health Genomics; 2014; 17(2):115-23. PubMed ID: 24714026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hungarian national plan and strategy for rare diseases].
    Kosztolányi G
    Orv Hetil; 2014 Mar; 155(9):325-8. PubMed ID: 24566695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National registries of rare diseases in Europe: an overview of the current situation and experiences.
    Taruscio D; Vittozzi L; Choquet R; Heimdal K; Iskrov G; Kodra Y; Landais P; Posada M; Stefanov R; Steinmueller C; Swinnen E; Van Oyen H
    Public Health Genomics; 2015; 18(1):20-5. PubMed ID: 25228300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transposition and implementation of EU rare disease policy in Eastern Europe.
    Pejcic AV; Iskrov G; Raycheva R; Stefanov R; Jakovljevic MM
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):557-566. PubMed ID: 28975845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Union Policy in the Field of Rare Diseases.
    Moliner AM; Waligora J
    Adv Exp Med Biol; 2017; 1031():561-587. PubMed ID: 29214592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polish activity within Orphanet Europe--state of art of database and services.
    Jezela-Stanek A; Karczmarewicz D; Chrzanowska KH; Krajewska-Walasek M
    Dev Period Med; 2015; 19(4):536-41. PubMed ID: 26982769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Legal assessment of current situation on orphan patients in Lithuania.
    Spokiene I
    Medicina (Kaunas); 2008; 44(8):571-6. PubMed ID: 18791333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating a European Union framework for actions in the field of rare diseases.
    Moliner AM
    Adv Exp Med Biol; 2010; 686():457-73. PubMed ID: 20824460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How the EUCERD Joint Action supported initiatives on Rare Diseases.
    Lynn S; Hedley V; Atalaia A; Evangelista T; Bushby K;
    Eur J Med Genet; 2017 Mar; 60(3):185-189. PubMed ID: 28087401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A review of the nutritional management plans in the member states of the European Union].
    Lachat C; Dehenauw S; van Camp J; Matthys C; Larondelle Y; Kolsteren P
    Verh K Acad Geneeskd Belg; 2006; 68(1):55-76. PubMed ID: 16610423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supporting health systems in Europe: added value of EU actions?
    Clemens T; Michelsen K; Brand H
    Health Econ Policy Law; 2014 Jan; 9(1):49-69. PubMed ID: 23968231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare diseases and orphan drugs.
    Taruscio D; Capozzoli F; Frank C
    Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.